Immatics N.V.
No enriched coverage for $IMTX in the last 7 days.
No SEC Form 4 filings for $IMTX in the last 30 days.
The article provides financial information for Immatics N.V. (MUN:4A3), specifically focusing on its operating cash flow per share. It presents the value, change, and percentage change for a given period, allowing investors to quickly assess this key financial metric.
Wall Street Zen upgraded Immatics (NASDAQ:IMTX) from a "sell" to a "hold" rating. This upgrade aligns with a broader analyst consensus of "Moderate Buy" for the clinical-stage biotechnology company, which focuses on T cell receptor (TCR)-based immunotherapies for solid tumors. Institutional investors, including T. Rowe Price and Baker Bros., have significantly increased their stakes in Immatics, which currently trades with a market cap of $1.22 billion.
Immatics (IMTX) delivered earnings and revenue surprises of +2.00% and -50.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
